Kairos Pharma, Ltd. (KAPA) Stock

Kairos Pharma, Ltd. (KAPA) is a Healthcare stock trading at $0.29 (as of 2026-08-21), with a market capitalization of $6.94M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company developing treatments for cancer patients, including antibody-based and small-molecule therapeutics. Its development programs target prostate cancer, lung cancer, breast cancer, and glioblastoma, and it is based in Los Angeles, California.

Valuation — source: SEC EDGAR (first-party)
Price$0.29
Market Cap$6.94M
Price / Book1.66
Profitability & Growth — source: SEC EDGAR
Return on Equity-138.5%
Current Ratio11.98
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderCITADEL ADVISORS LLC ($228434.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJohn S. Yu
Employees1
CountryUS
IPO Date2024-09-16

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Adial Pharmaceuticals, Inc. (ADIL)
  • Imunon, Inc. (IMNN)
  • Traws Pharma, Inc. (TRAW)
  • CNS Pharmaceuticals, Inc. (CNSP)
  • Soligenix, Inc. (SNGX)
  • GeoVax Labs, Inc. (GOVX)
  • Exicure, Inc. (XCUR)
  • Azitra, Inc. (AZTR)
KAPA earnings history · KAPA institutional & insider holders · KAPA KPIs & operating metrics · KAPA financials · KAPA investor presentations & press releases · KAPA SEC filings · KAPA peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.